Steward Partners Investment Advisory LLC Sells 1,584 Shares of Moderna, Inc. (NASDAQ:MRNA)

Steward Partners Investment Advisory LLC cut its holdings in shares of Moderna, Inc. (NASDAQ:MRNA) by 33.4% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 3,162 shares of the company’s stock after selling 1,584 shares during the period. Steward Partners Investment Advisory LLC’s holdings in Moderna were worth $131,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Banco Santander S.A. bought a new position in Moderna in the third quarter valued at about $3,550,000. John G Ullman & Associates Inc. raised its position in shares of Moderna by 341.3% during the third quarter. John G Ullman & Associates Inc. now owns 49,650 shares of the company’s stock worth $3,318,000 after acquiring an additional 38,400 shares during the last quarter. abrdn plc raised its position in shares of Moderna by 28.1% during the fourth quarter. abrdn plc now owns 315,912 shares of the company’s stock worth $12,842,000 after acquiring an additional 69,360 shares during the last quarter. Y Intercept Hong Kong Ltd raised its position in shares of Moderna by 30.9% during the third quarter. Y Intercept Hong Kong Ltd now owns 101,159 shares of the company’s stock worth $6,760,000 after acquiring an additional 23,881 shares during the last quarter. Finally, Spire Wealth Management raised its position in shares of Moderna by 2,150.4% during the fourth quarter. Spire Wealth Management now owns 23,224 shares of the company’s stock worth $966,000 after acquiring an additional 22,192 shares during the last quarter. Institutional investors own 75.33% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on MRNA. UBS Group lowered their price objective on Moderna from $96.00 to $78.00 and set a “buy” rating for the company in a research report on Wednesday, February 19th. Hsbc Global Res raised Moderna from a “hold” rating to a “strong-buy” rating in a research report on Monday, November 18th. JPMorgan Chase & Co. set a $45.00 target price on Moderna in a research report on Friday, February 14th. Leerink Partners decreased their price objective on Moderna from $31.00 to $27.00 and set an “underweight” rating for the company in a report on Thursday, January 16th. Finally, Royal Bank of Canada restated a “sector perform” rating and set a $40.00 price target on shares of Moderna in a research note on Tuesday, February 18th. Four research analysts have rated the stock with a sell rating, sixteen have issued a hold rating, three have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Moderna has an average rating of “Hold” and a consensus price target of $59.60.

Moderna Stock Up 0.9 %

MRNA stock opened at $34.62 on Monday. The firm has a market cap of $13.36 billion, a PE ratio of -3.73 and a beta of 1.86. The business has a 50 day moving average of $35.94 and a 200-day moving average of $47.15. Moderna, Inc. has a 12-month low of $29.25 and a 12-month high of $170.47.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.